Therefore, it is of high significance for treatment of inflammation, metabolic diseases, and inhibiting of tumor growth to develop new dual inhibitors with good pharmacokinetics and biochemical characteristics to target FABP4 and FABP5. This evidence concerns the gene FABP4 and Other metabolic disease.